Pearl Diagnostics
Baltimore, US · Founded 2022 · 3 known investors
Pearl Diagnostics develops non-culture-based diagnostic tests that detect fungal and other pathogen antigens in urine, including the MycoMEIA Aspergillus Assay for diagnosing invasive aspergillosis. The company, a Johns Hopkins spinout formerly known as MycoMed Technologies, provides clinical diagnostic tools for health care providers.
BiotechDigital HealthHealthtechMedical Devices
Founders & leadership
Pearl Diagnostics was founded in 2022 by Kieren Marr and MaryAnn Shallcross.
KM
Kieren MarrCo-founder
MS
MaryAnn ShallcrossCo-founder
EG
Eric GornsteinExecutive
Board
JC
John CammackBoard director
BS
Brad SpellbergBoard director
Investors · 3
Competitors · 2
by search overlapGetlabs4 shared keywordsGetlabs provides at-home lab sample collection, sending phlebotomists to patients to draw blood and collect samples for lab tests ordered by their providers. Lab results are shared directly with the patient and the ordering provider, with support for connecting results to the Apple Health app.
Perlara3 shared keywordsPerlara is a biopharmaceutical company that develops treatments for ultra-rare genetic diseases using yeast-based disease modeling and drug repurposing strategies. The company operates as a full-stack drug development platform serving rare disease patients and families.
Companies competing with Pearl Diagnostics for the same Google search keywords, organic and paid, via search-intersection analysis.
Reported raises · per SEC filings
Form D private placements$14.7M disclosed across 2 rounds · 2022–2026
▶$11.2MraisedApr 2026 · 21 investors · BiotechnologyRule 506(b)
▶$11.2MraisedApr 2026 · 21 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Brad SpellbergDirector
- Eric GornsteinExecutive Officer, Director
- John CammackDirector
- Kieren MarrExecutive Officer, Director
- Offering amount
- $11.2M
- Amount sold
- $11.2M
- Minimum investment
- $56.5K
- Proceeds to insiders
- $500K
- First sale
- Mar 2026
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
▶$3.5MraisedJun 2022 · 11 investors · BiotechnologyRule 506(b)
▶$3.5MraisedJun 2022 · 11 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Kieren MarrExecutive Officer, Director
- Brad SpellbergDirector
- John CammackDirector
- Offering amount
- $3.5M
- Amount sold
- $3.5M
- Minimum investment
- $100K
- Proceeds to insiders
- $100K
- First sale
- Feb 2022
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Pearl Diagnostics do?
- Pearl Diagnostics develops non-culture-based diagnostic tests that detect fungal and other pathogen antigens in urine, including the MycoMEIA Aspergillus Assay for diagnosing invasive aspergillosis. The company, a Johns Hopkins spinout formerly known as MycoMed Technologies, provides clinical diagnostic tools for health care providers.
- Who founded Pearl Diagnostics?
- Pearl Diagnostics was founded by Kieren Marr, MaryAnn Shallcross in 2022.
- Who are Pearl Diagnostics's investors?
- Pearl Diagnostics's investors include Maryland TEDCO, Rembrandt Venture Partners, TEDCO.
- How much funding has Pearl Diagnostics raised?
- Pearl Diagnostics has disclosed $14.7M raised across 2 rounds.
- Where is Pearl Diagnostics headquartered?
- Pearl Diagnostics is headquartered in Baltimore, US.